Navigation Links
Other stomach microbiota modulate resistance to H. pylori-driven ulcers
Date:3/25/2013

WASHINGTON, DC March 25, 2013 Mice with different naturally occurring stomach bacteria have distinct susceptibilities to disease caused by Helicobacter pylori, the well-known cause of ulcers in humans, according to a study published online ahead of print in the journal Infection and Immunity. This is the first study to document (in mice) that the presence of certain bacteria in the stomach microbiota can prevent pathology from H. pylori.

The gastro-intestinal tract is a veritable ecosystem packed with microbes, and over the last decade, investigators have been discovering that the species composition of that ecosystem can have a profound effect on human health. But the eureka moment that led to this study came "when we realized that mice from different vendors mount different responses to H. pylori infection," says principal investigator Karen Ottemann of the University of California, Santa Cruz.

Following this discovery, the researchers divided mice from the vendor, Taconic Farms, into three groups: mice treated with antibiotics in order to kill some of the resident bacteria, mice that were fed normal stomach bacteria after antibiotic treatment, and mice that were not treated. They then infected each group with H. pylori, and assayed the animals' stomachs for immune system cells.

"The antibiotic-treated mice had small quantities of particular inflammatory cells, called Th1 T helper cells," says Ottemann. Both the untreated mice, and the treated mice that were then fed normal stomach bacteria had normal (higher) levels of Th1 T helper cells. These results suggested that the normal stomach microbes contribute to disease caused by H. pylori, says Ottemann.

The researchers then determined that around 4,000 species of bacteria were different in the high- and low-inflammation (no antibiotics, and antibiotic-treated, respectively) mice. Notably, the mice with low inflammation "had elevated amounts of Clostridia, bacteria known to prevent inflammation in the intestine," says Ottemann. Thus, the Clostridia may be key to dampening H. pylori pathology, although that remains to be determined, she says.

Ottemann says that this research may lead to predicting future H. pylori disease, including ulcers and gastric cancer -- which has few treatment options and high mortality -- based on stomach microbiota.

"After we determine which microbes underlie H. pylori disease outcomes, we could test whether H. pylori-infected people harbor those particular bacteria, and target them for curing," says Ottemann. Alternatively, such people could receive the protective bacteria as probiotics. The latter might be a superior option, because while prone to ulcers in middle and advanced age, people who harbor H. pylori are less likely to get esophageal cancer and asthma.


'/>"/>
Contact: Garth Hogan
ghogan@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related medicine news :

1. New insights into when beach sand may become unsafe for digging and other contact
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Immunotherapy for elderly cancer patients finds new promise in drug combination
4. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
5. Concerns about MRSA for expectant mothers may be unfounded
6. Another Drug Take-Back Day Scheduled for Saturday
7. Low-Income Mothers May Overfeed Their Infants
8. New global report says US lags behind 130 other nations in preterm birth rate
9. Screening for Other Health Problems May Aid COPD Survival
10. Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
11. Genetic predictor of breast cancer response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist ... new pediatric patients, with or without a referral. Dr. Cotey knows that interceptive ... outcome and experience. When patients receive early treatment, they may achieve straight teeth with ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce ... million gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access ... MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  The leader in accelerated ... Drs. Sam Daher , Manal Ibrahim , ... David Couchat will be the featured microlecture presenters at ... American Association of Orthodontists (AAO) Annual Session, April 21-25, ... the microlectures beginning daily at 11:20 a.m. On the ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
Breaking Medicine Technology: